This may be an unpopular opinion, but I do not wan
Post# of 157598
(Total Views: 485)
Posted On: 09/09/2025 10:41:27 PM
This may be an unpopular opinion, but I do not want us to uplist anytime soon. If we spike to $4+ somehow and uplist but we don't have revenue, the share price will begin to fall. When it gets under a dollar again, we will be forced to reverse split or face being delisted which would be terrible. Trust me, I got burned by that on Cel-Sci (CVM) and I'm still waiting to get out of the hole. I almost got burned on Tonix Pharmaceuticals (TNXP) but I timed some things right there and made a decent return.
Uplisting before approval or before steady revenue is not a good idea for a biotech because the FDA can always slow walk us, make us run confirmatory trials (what happened to CVM), and/or just have things end up taking longer than expected to come to market. The big boys care about earnings season and if you have no earnings, your value will drop.
Uplisting before approval or before steady revenue is not a good idea for a biotech because the FDA can always slow walk us, make us run confirmatory trials (what happened to CVM), and/or just have things end up taking longer than expected to come to market. The big boys care about earnings season and if you have no earnings, your value will drop.
(6)
(0)